OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Director exercised or converted 5,000 GILD derivative securities | OQRO

Home
Insider trades
Gilead Sciences
Director exercised or converted 5,000 GILD derivative securities

Insider trades

Insider trade

Director exercised or converted 5,000 GILD derivative securities

Traded Jan 20, 2026 · Filed Jan 21, 2026

GILGilead SciencesGILD

5,000
Shares · @ $67.45

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jan 20, 2026
Reporting period: Not applicable
Filed with the SEC: Jan 21, 2026

DirectorOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001771814-26-000002

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Jan 21, 2026, 9:26 PM UTC

Added to OQRO

Oct 2, 2026, 12:27 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

GILEAD SCIENCES, INC.

Issuer CIK

882095

Ticker

GILD

Reporting person

Jeffrey Bluestone

Relationship

Director

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Jan 20, 2026

Transaction code

Shares / units

5,000

Price per share

$67.45

Acquired / disposed

Acquired (A)

Shares owned after

13,920

Ownership form

Direct

Amendment

Footnotes from the filing

The transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.

Around the same time

Johanna MercierChief Comm & Corp Aff Officer

Filed 8mo ago

25KShares · @ $66.64

Traded Feb 17 · filed 1 day later

Derivative exercise or conversion — not an open-market buy.

More Official record

Johanna Mercier (Chief Comm & Corp Aff Officer) sold ~$2.84M of Gilead Sciences

Scheduled in advanceFiled 8mo ago

Johanna Mercier (Chief Comm & Corp Aff Officer) sold ~$1.46M of Gilead Sciences

Scheduled in advanceFiled 8mo ago